AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01519765
Drug: Buccal Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal rather than Vaginal misoprostol for induction of labor
Trial: NCT01519765
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal rather than buccal misoprostol for induction of labor
Trial: NCT00495118
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03433001
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib capsules
Trial: NCT03433001
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules
Trial: NCT03433001
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone tablets
Trial: NCT03043274
Drug: Cangrelor
RxNorm normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
Trial: NCT02386592
Drug: Chlorhexidine gluconate (CHG)
RxNorm normalized name: QCare Oral Cleansing and Suctioning System compatible with 0.12% Chlorhexidine Gluconate (CHG) Oral Rinse KIT
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
Trial: NCT02950766
Drug: NeoVax
RxNorm normalized name: Neova Complex HQ Plus
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination of Neoantigen peptides and poly-ICLC
Trial: NCT02950766
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: local administration of ipilimumab
Trial: NCT03240016
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg IV D1
Trial: NCT03240016
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg/m\^2 D1 and D8
Trial: NCT04251533
Drug: alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg orally, once per day (QD), tablets
Trial: NCT04251533
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg/m\^2 IV infusion, once per day (QD)
Trial: NCT03913442
Drug: Colchicine 0.8 mg or 0.6 mg orally once daily
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
Trial: NCT01423435
Drug: TRK-100STP
RxNorm normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00003390
Drug: irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00281619
Drug: CellCept (mycophenolate mofetil)
RxNorm normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02742090
Drug: Umbralisib
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbralisib was administered as a tablet(s), orally once daily.
Trial: NCT03937843
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
Trial: NCT03937843
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.
Trial: NCT03937843
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.
Trial: NCT04221451
Drug: venglustat GZ402671
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT04268199
Drug: Bortezomib Injection
RxNorm normalized name: bortezomib Injection
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection
Trial: NCT03128021
Drug: Escitalopram Pill
RxNorm normalized name: escitalopram Pill
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blinded, randomly assigned
Trial: NCT03128021
Drug: Levomilnacipran Pill
RxNorm normalized name: levomilnacipran Pill
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blinded, randomly assigned
Trial: NCT04597541
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
Trial: NCT00095784
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT03629340
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
Trial: NCT01162499
Drug: Exendin-(9-39)
RxNorm normalized name: Exendin 4
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of exendin-(9-39) for 5 hours
Trial: NCT01705899
Drug: Human Pancreatic Islets
RxNorm normalized name: Allogeneic human pancreatic islets of Langerhans
DrugBank: Allogeneic human pancreatic islets of Langerhans (DB18651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
Trial: NCT01697306
Drug: Gemcitabine 2 g
RxNorm normalized name: gemcitabine 2 GM Injection
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
Trial: NCT01697306
Drug: BCG Vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
Trial: NCT01043224
Drug: Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily application
Trial: NCT04495621
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab solution for infusion administered weekly via IV infusion.
Trial: NCT02160782
Drug: LUM001 (Maralixibat)
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
Trial: NCT00195572
Drug: TS-1
RxNorm normalized name: CTS-1027
DrugBank: Gimeracil (DB09257)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00171509
Drug: Cyclosporine microemulsion
RxNorm normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00400231
Drug: Study drugs: Metformin and fenofibrate
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
Trial: NCT00400231
Drug: Study Drug: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2000mg/day
Trial: NCT00400231
Drug: Study Drug: fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 145mg/day of fenofibrate
Trial: NCT00322309
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
Trial: NCT00400231
Drug: Metformin and Fenofibrate placebo
RxNorm normalized name: simvastatin and fenofibrate
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: placebo metformin and fenofibrate
Trial: NCT00970073
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg PO/IV BID for up to 6 months
Trial: NCT00970073
Drug: tacrolimus 3-8
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
Trial: NCT00970073
Drug: tacrolimus 8-12
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
Trial: NCT01757262
Drug: 90 mg Ticagrelor
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morning and Evening dose for 5 days
Trial: NCT01757262
Drug: 75mg Clopidogrel
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Morning dose for 5 days
Trial: NCT02421029
Drug: edetate calcium disodium
RxNorm normalized name: Edetate Calcium Disodium
DrugBank: Edetate calcium disodium anhydrous (DB14598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
Trial: NCT03518606
Drug: Durvalumab + Tremelimumab + metronomic Vinorelbine
RxNorm normalized name: tremelimumab
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
Trial: NCT01289509
Drug: E5501
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lot P01010ZZA (test) single oral doses of 40 mg tablets.
Trial: NCT00555009
Drug: Genotropin
RxNorm normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
Trial: NCT03337607
Drug: Eperisone
RxNorm normalized name: Eperisone
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 50 mg per day for four weeks
Trial: NCT02460458
Drug: Von Willebrand Factor
RxNorm normalized name: Von Willebrand Factor
DrugBank: Vonicog alfa (DB12872)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
Trial: NCT00174733
Drug: Ciclesonide (XRP1526)
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03844048
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral; film-coated tablets or tablets for oral suspension
Trial: NCT03664830
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
Trial: NCT00359853
Drug: Oral norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00403286
Drug: Fluticasone Propionate/Formoterol Fumarate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
Trial: NCT00403286
Drug: Fluticasone Propionate/Formoterol Fumarate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
Trial: NCT00403286
Drug: Fluticasone Propionate/Formoterol Fumarate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
Trial: NCT00403286
Drug: Fluticasone Propionate/Formoterol Fumarate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
Trial: NCT00403286
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
Trial: NCT00403286
Drug: Formoterol Fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation Solution for nebulization 20 mcg bid for 2 weeks
Trial: NCT00403286
Drug: Fluticasone Propionate/Salmeterol Xinafoate
RxNorm normalized name: Fluticasone Propionate/Salmeterol Xinafoate 0.1 MG/1 ACTUATION-0.05 MG/1 ACTUATION Inhalation Disk
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
Trial: NCT02884206
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
Trial: NCT02260440
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be given at 200 mg every 21 days
Trial: NCT02260440
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
Trial: NCT02884206
Drug: Placebo of Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
Trial: NCT00330421
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00000464
Drug: amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000464
Drug: imipramine
RxNorm normalized name: Imipramine
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000464
Drug: mexiletine
RxNorm normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00398411
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg p.o. per day
Trial: NCT00000464
Drug: procainamide
RxNorm normalized name: Procainamide
DrugBank: Procainamide (DB01035)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000464
Drug: propafenone
RxNorm normalized name: Propafenone
DrugBank: Propafenone (DB01182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000464
Drug: quinidine
RxNorm normalized name: Quinidine
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000464
Drug: sotalol
RxNorm normalized name: Sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01765556
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple doses of ketoconazole in Period B and C
Trial: NCT01765556
Drug: vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of vemurafenib in Period A and C
Trial: NCT03244956
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mg daily for a maximum of 6 weeks of treatment
Trial: NCT03244956
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150mg twice daily
Trial: NCT03244956
Drug: rhTSH
RxNorm normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9mg on two consecutive days after 35 days of treatment
Trial: NCT02326428
Drug: Intravenous thrombolysis by alteplase (Actilyse) (optional)
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
Trial: NCT01988311
Drug: psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose manipulation as described in the protocol
Trial: NCT00950742
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Load: 4mg/kg-maintain:2mg/kg/week
Trial: NCT00608205
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01070641
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5mg QD
Trial: NCT01417897
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Trial: NCT01417897
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Trial: NCT00057447
Drug: Interferon Gamma-1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 mcg, SQ, 3x per week
Trial: NCT00057447
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg per square meters, IV, 1x per week
Trial: NCT00654121
Drug: Actrapid HM
RxNorm normalized name: DEXTRAN HM
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
Trial: NCT00537238
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
Trial: NCT00537238
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
Trial: NCT00046423
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01630200
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast coated tablet, 500µg oral application, once daily in the morning
Trial: NCT01863953
Drug: Fixed-Combination Bimatoprost/Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
Trial: NCT01863953
Drug: Bimatoprost Ophthalmic Solution 0.01%
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.